ArticleMarine drugs2011
Bactericidal kinetics of marine-derived napyradiomycins against contemporary methicillin-resistant Staphylococcus aureus.
Article in Marine drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Insights for napyradiomycin family: structures, bioactivities and biosynthetic pathways.Archives of microbiology · 2025Review
- Synthesis and Biological Evaluation of Novel Fusidic Acid Derivatives as Two-in-One Agent with Potent Antibacterial and Anti-Inflammatory Activity.Antibiotics (Basel, Switzerland) · 2022Article
- Marine Actinobacteria a New Source of Antibacterial Metabolites to Treat Acne Vulgaris Disease-A Systematic Literature Review.Antibiotics (Basel, Switzerland) · 2022Review
- Biological activities of meroterpenoids isolated from different sources.Frontiers in pharmacology · 2022Review
- Mersaquinone, A New Tetracene Derivative from the Marine-DerivedAntibiotics (Basel, Switzerland) · 2020Article
- New Napyradiomycin Analogues fromMarine drugs · 2019Article
- Total Enzyme Syntheses of Napyradiomycins A1 and B1.Journal of the American Chemical Society · 2018Article
- Bioactive Prenyl- and Terpenyl-Quinones/Hydroquinones of Marine OriginMarine drugs · 2018Review
- Review
- A unifying paradigm for naphthoquinone-based meroterpenoid (bio)synthesis.Nature chemistry · 2017Article
- MDN-0170, a New Napyradiomycin from Streptomyces sp. Strain CA-271078.Marine drugs · 2016Article
- Broad targeting of resistance to apoptosis in cancer.Seminars in cancer biology · 2015Review
- Napyradiomycins CNQ525.510B and A80915C target the Hsp90 paralogue Grp94.Organic & biomolecular chemistry · 2014Article
- Antibacterial and cytotoxic new napyradiomycins from the marine-derived Streptomyces sp. SCSIO 10428.Marine drugs · 2013Article
- Cytotoxic and Antimicrobial Napyradiomycins from Two Marine-Derived, MAR 4European journal of organic chemistry · 2013Article
- Efficacy of NZ2114, a novel plectasin-derived cationic antimicrobial peptide antibiotic, in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
There is an urgent need for new antibiotics to treat hospital- and community-associated methicillin-resistant Staphylococcus aureus (MRSA) infections. Previous work has indicated that both terrestrial and marine-derived members of the napyradiomycin class possess potential anti-staphylococcal activities. These compounds are unique meroterpenoids with unusual levels of halogenation. In this paper we report the evaluation of two previously described napyradiomycin derivatives, A80915A (1) and A80915B (2) produced by the marine-derived actinomycete, Streptomyces sp. strain CNQ-525, for their specific activities against contemporary and clinically relevant MRSA. Reported are studies of the in vitro kinetics of these chemical scaffolds in time-kill MRSA assays. Both napyradiomycin derivatives demonstrate potent and rapid bactericidal activity against contemporary MRSA strains. These data may help guide future development and design of analogs of the napyradiomycins that could potentially serve as useful anti-MRSA therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.